13 July 2021
Vermont Attorney General's Office
109 State Street
Montpelier, VT 05609

RE: New Prescription Drug – 30 Day Notice

Dear Sir or Madam,

On 17 June 2021, Myovant Sciences Inc. notified the Office of the Attorney General of Vermont of a new prescription drug (MYFEMBFREE), pursuant to § 4637(b). Myovant Sciences Inc. hereby notifies the Attorney General of Vermont of the following information, pursuant to §4637(c):

NDC	PRODUCT	PACKAGE SIZE
72974-415-01	MYFEMBREE (relugolix 40 mg, estradiol 1 mg and norethindrone acetate 0.5 mg) tablets	28 tablets

Description of the marketing and pricing plans used in the launch of MYFEMBREE in the United States:
Myovant Sciences Inc. does not believe this information is in the public domain or publicly available. Accordingly, Myovant Sciences Inc. is limiting its response to this item pursuant to §4637(d).

The estimated volume of patients who may be prescribed MYFEMBREE:
MYFEMBREE is a combination of relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, estradiol, an estrogen, and norethindrone acetate, a progestin, indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. An estimated five million women in the U.S. suffer from symptoms of uterine fibroids, which may include heavy menstrual bleeding, pain, and anemia.

WAC represents the manufacturer's published catalog or list price for a drug product to wholesalers as reported to third-party pricing publishers. WAC does not represent actual transaction prices and does not include discounts, rebates, or reduction in price. Pricing information listed does not imply safety or efficacy of the product, and no comparisons should be made.

Whether the drug was granted breakthrough therapy designation or priority review by the FDA prior to final approval:
MYFEMBREE did not receive breakthrough therapy designation nor priority review by the FDA.

The date and price of acquisition if the drug was not developed by the manufacturer:
N/A

Please do not hesitate to contact us if you have any questions.

Regards,

DocuSigned by:
Raymond Wang
7EF4D5010CFD44D...

Raymond Wang
Associate Director, Pricing & Contracting
Myovant Sciences, Inc.